The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
The emergence of new infections in India is a growing concern
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Subscribe To Our Newsletter & Stay Updated
